| Literature DB >> 25365066 |
K Gagne1, P Loiseau2, V Dubois3, F Dufossé4, P Perrier5, A Dormoy6, I Jollet7, V Renac8, D Masson9, C Picard10, X Lafarge11, D Hanau12, F Quainon13, F Delbos14, B Coeffic15, Léna Absi16, J-F Eliaou17, V Moalic18, M Fort19, M de Matteis20, I Theodorou21, F Hau22, A Batho23, B Pedron24, S Caillat-Zucman25, E Marry26, N Raus27, I Yakoub-Agha27, A Cesbron28.
Abstract
We retrospectively analyzed the impact of HLA-DPB1 mismatches in a large cohort of 1342 French patients who underwent 10/10 HLA-matched unrelated HSCT. A significant impact of HLA-DPB1 allelic mismatches (2 vs 0) was observed in severe acute GVHD (aGVHDIII-IV) (risk ratio (RR)=1.73, confidence interval (CI) 95% 1.09-2.73, P=0.019) without impact on OS, TRM, relapse and chronic GVHD (cGVHD). According to the T-cell epitope 3 (TCE3)/TCE4 HLA-DPB1 disparity algorithm, 37.6% and 58.4% pairs had nonpermissive HLA-DPB1, respectively. TCE3 and TCE4 disparities had no statistical impact on OS, TRM, relapse, aGVHD and cGVHD. When TCE3/TCE4 disparities were analyzed in the graft-vs-host or host-vs-graft (HVG) direction, only a significant impact of TCE4 nonpermissive disparities in the HVG direction was observed on relapse (RR=1.34, CI 95% 1.00-1.80, P=0.048). In conclusion, this French retrospective study shows an adverse prognosis of HLA-DPB1 mismatches (2 vs 0) on severe aGVHD and of nonpermissive TCE4 HVG disparities on relapse after HLA-matched 10/10 unrelated HSCT.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25365066 DOI： 10.1038/bmt.2014.253
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483